Polyrizon Ltd. (PLRZ)

$1.55 -0.09 (-5.49%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,429,814
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Latest News on PLRZ

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 25, 2025, 7:37 AM EDT - 23 hours ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 11, 2025, 4:15 PM EDT - 14 days ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 2, 2025, 9:05 AM EDT - 23 days ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Apr 1, 2025, 4:09 PM EDT - 24 days ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 25 days ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 27, 2025, 8:25 AM EDT - 4 weeks ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 25, 2025, 4:04 PM EDT - 4 weeks ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 14, 2025, 8:35 AM EDT - 6 weeks ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 13, 2025, 7:51 AM EDT - 6 weeks ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 11, 2025, 4:27 PM EDT - 6 weeks ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Mar 10, 2025, 7:47 AM EDT - 6 weeks ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 30, 2025, 5:55 AM EST - 3 months ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Jan 23, 2025, 6:40 AM EST - 3 months ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Dec 30, 2024, 6:25 AM EST - 4 months ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Dec 19, 2024, 7:22 AM EST - 4 months ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Dec 18, 2024, 6:25 AM EST - 4 months ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Dec 13, 2024, 6:25 AM EST - 4 months ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Dec 2, 2024, 8:02 AM EST - 5 months ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Oct 30, 2024, 1:50 PM EDT - 6 months ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Oct 30, 2024, 10:28 AM EDT - 6 months ago

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

Oct 28, 2024, 7:02 PM EDT - 6 months ago

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

Polyrizon IPO Registration Document (F-1)

Oct 6, 2022, 6:57 PM EDT - 2 years ago

Polyrizon IPO Registration Document (F-1)